Applying Different Techniques to Improve the Bioavailability of Candesartan Cilexetil Antihypertensive Drug

被引:17
作者
Aly, Usama Farghaly [1 ]
Sarhan, Hatem Abdelmonsef [1 ]
Ali, Taha F. S. [2 ]
Sharkawy, Hosny Abd El-Bakey [1 ]
机构
[1] Menia Univ, Fac Pharm, Dept Pharmaceut, Assuit Agr Rd,PO 61519, Al Minya, Egypt
[2] Menia Univ, Fac Pharm, Dept Med Chem, Al Minya, Egypt
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2020年 / 14卷
关键词
solid dispersion; inclusion complex; nanoparticles; pharmacokinetics; UPLC MS/MS; SOLID DISPERSION; DISSOLUTION; CYCLODEXTRIN; HYPERTENSION; COMPLEXES; SYSTEMS; K-30;
D O I
10.2147/DDDT.S248511
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Purpose: The objective of this study was to compare different techniques to enhance the solubility and dissolution rate, and hence the bioavailability of candesartan cilexetil. Methods: To achieve this target, various techniques were employed such as solid dispersions, inclusion complexes, and preparation of candesartan nanoparticles. Following the preparations, all samples were characterized for their physicochemical properties, and the samples of the best results were subjected to further bioavailability studies. Results: Results of dissolution studies revealed an increase in the dissolution rate of all samples. The highest dissolution rate was achieved using solid dispersion of the drug with PVP K-90 (1:4). Physicochemical investigations (XR, DSC, and FT-IR) suggested formation of hydrogen bonding and changing in the crystalline structure of the drug. Regarding the inclusion complexes, more stable complex was formed between HP-beta-CD and CC compared to beta-CD, as indicated by phase solubility diagrams. Antisolvent method resulted in the preparation of stable nanoparticles, as indicated by zeta potential, with average particle size of 238.9 +/- 19.25 nm using PVP K-90 as a hydrophilic polymer. The best sample that gave the highest dissolution rate (CC/PVP K-90 1:4) was allowed for further pharmacokinetic studies using UPLC MS/MS assay of rabbit plasma. Results showed a significant increase in the bioavailability of CC from similar to 15% to similar to 48%. Conclusion: The bioavailability of CC was significantly improved from similar to 15% to similar to 48% when formulated as SDs with PVP K-90 with 1:4 drug:polymer ratio.
引用
收藏
页码:1851 / 1865
页数:15
相关论文
共 46 条
  • [21] IMPROVEMENT OF SOLUBILITY AND DISSOLUTION RATE OF CANDESARTAN CILEXETIL BY SOLID DISPERSION IN POLYVINYL PYRROLIDONE
    Katti, Vishal S.
    Kadam, Atul M.
    Honmane, Sandip M.
    Patil, Shitalkumar
    Patil, Sachin
    Bhamare, Kiran
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2014, 5 (04): : 1550 - 1556
  • [22] The formation of a host-guest inclusion complex system between -cyclodextrin and baicalin and its dissolution characteristics
    Li, Jing
    Jiang, Qihua
    Deng, Ping
    Chen, Qian
    Yu, Mingan
    Shang, Jingchuan
    Li, Wei
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2017, 69 (06) : 663 - 674
  • [23] Investigation of PEG 6000/Tween 80/Span 80/H2O niosome microstructure
    Liu, Tianqing
    Guo, Rong
    [J]. COLLOID AND POLYMER SCIENCE, 2007, 285 (06) : 711 - 713
  • [24] Pharmaceutical strategies of improving oral systemic bioavailability of curcumin for clinical application
    Ma, Ziwei
    Wang, Na
    He, Haibing
    Tang, Xing
    [J]. JOURNAL OF CONTROLLED RELEASE, 2019, 316 : 359 - 380
  • [25] Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins
    Mady, Fatma M.
    Aly, Usama Farghaly
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 1681 - 1692
  • [26] Analysis of physicochemical properties of ternary systems of oxaprozin with randomly methylated-ss-cyclodextrin and L-arginine aimed to improve the drug solubility
    Mennini, Natascia
    Maestrelli, Francesca
    Cirri, Marzia
    Mura, Paola
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2016, 129 : 350 - 358
  • [27] Candesartan cilexetil - a review of effects on cardiovascular complications in hypertension and chronic heart failure
    Meredith, Peter A.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (07) : 1693 - 1705
  • [28] Mohanraj V. J., 2006, Tropical Journal of Pharmaceutical Research, V5, P561
  • [29] Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future
    Muller, RH
    Jacobs, C
    Kayser, O
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) : 3 - 19
  • [30] National Research Council, 2012, GUIDE CARE USE LAB A